Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Gilead Sciences, Inc.

Market Cap 154B 224,800B 134B 124B 116B 217B 14,491B 219B 1,471B 570B 7,134B 577B 564B 24,782B P/E 2026 *
-44.3x
P/E 2027 * 16.1x
Enterprise Value 163B 238,798B 142B 132B 123B 231B 15,394B 233B 1,563B 606B 7,578B 613B 599B 26,325B EV / Sales 2026 *
5.36x
EV / Sales 2027 * 4.73x
Free-Float
99.87%
Yield 2026 *
2.62%
Yield 2027 * 2.68%
1 day+4.04%
1 week+2.98%
Current month-2.85%
1 month+0.25%
3 months-6.48%
6 months+2.72%
Current year+3.33%
1 week 44,980
Extreme 44980
48,620
1 month 44,980
Extreme 44980
50,975
Current year 44,320
Extreme 44320
58,100
1 year 31,025
Extreme 31025
58,100
3 years 9,500
Extreme 9500
58,100
5 years 2,682.5
Extreme 2682.5
58,100
10 years 656.5
Extreme 656.5
58,100
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Change 5-day change 1-year change 3-year change Capi.($)
+4.04%+2.98% - - 154B
-1.21%-5.37%+39.94%+145.38% 980B
-2.48%-4.17%+51.52%+39.07% 550B
-2.14%-3.68%+16.71%+56.15% 382B
-1.18%+0.25%+25.86%+16.53% 317B
+0.61%-2.53%+25.46%+12.27% 270B
+0.22%-2.67%+24.57%+30.34% 269B
+4.59%+3.68%-39.28%-46.92% 191B
-1.19%-4.65%+16.56%+47.00% 182B
-2.74%-3.67%+5.57%-37.07% 144B
Average -0.15%-2.90%+18.55%+29.19% 364.9B
Weighted average by Cap. -0.77%-3.47%+27.97%+59.80%

Financials

2026 *2027 *
Net sales 30.48B 44,590B 26.58B 24.58B 23.03B 43.12B 2,874B 43.47B 292B 113B 1,415B 114B 112B 4,916B 32.45B 47,475B 28.3B 26.17B 24.52B 45.91B 3,060B 46.28B 311B 120B 1,507B 122B 119B 5,234B
Net income -3.37B -4,934B -2.94B -2.72B -2.55B -4.77B -318B -4.81B -32.29B -12.51B -157B -12.66B -12.39B -544B 9.6B 14,049B 8.37B 7.74B 7.26B 13.59B 906B 13.7B 91.94B 35.63B 446B 36.04B 35.27B 1,549B
Net Debt 9.57B 13,998B 8.34B 7.72B 7.23B 13.54B 902B 13.65B 91.61B 35.5B 444B 35.91B 35.14B 1,543B -96.43M -141B -84.09M -77.76M -72.88M -136M -9.09B -138M -923M -358M -4.48B -362M -354M -15.55B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-06-19 48,420.00 $ +4.04% 110
26-06-18 46,540.00 $ -1.31% 1,651
26-06-17 47,160.00 $ -1.13% 440
26-06-16 47,700.00 $ +2.32% 337
26-06-12 46,620.00 $ -0.85% 771
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
123.76USD
Average target price
157.57USD
Spread / Average Target
+27.32%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!